Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

To be considered for this study, children need to be at least 1 year old and young adults up to 25 years old. They must have a confirmed diagnosis of specific types of Non-Hodgkin Lymphoma, including Burkitt's lymphoma or a similar type, or another aggressive B-cell lymphoma.

Crucially, the lymphoma must have either returned after previous treatment or not responded well to those treatments. Doctors will need to confirm this from existing medical tests. Participants also need to have generally recovered from any side effects of their previous cancer treatments and be in reasonably good health overall.

However, there are some reasons why someone might not be able to join. For example, if the lymphoma has spread to the brain or spinal cord (unless it's only in the fluid around them), or if they have another cancer that needs treatment. Also, participants shouldn't be receiving other ongoing cancer treatments at the time of joining.

If you join this study, you'll receive the study medicine, epcoritamab, as an injection under your skin. This will happen in treatment cycles, each lasting 28 days. You will need to attend regular appointments at a hospital or clinic approved for the study. These appointments will involve various medical checks to see how you're doing and how the treatment is affecting you.

These checks will include blood tests, filling out questionnaires about your health, and doctors regularly looking for any side effects. Because this is a research study, you might have more appointments and tests than you would normally expect with standard care. After you start the study, you'll be followed closely for at least three years, even after you stop receiving the study medicine.